Avizakimab, formerly known as BOS161721, represents a innovative medicinal approach to treating immune-mediated disorders. This biological agent selectively targets IL18, a crucial cytokine implicated in the https://alyshaffoc711737.aboutyoublog.com/53356203/avizakimab-a-thorough-investigation-into-bos161721-s-promise